Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
1149
¥ million (increase in revenue from results for the fiscal year ended March 2026 to the plan for the fiscal year ending March 2029)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales+23.3%
基準 4,939Target6,088million
Operating profit+0.1%
基準 2,026Target2,029million
Net income for the current fiscal year+0.1%
基準 2,026Target2,029million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Investment amount by sectorField Facilities for storing products and raw materials, including break rooms and changing rooms / Timing Fiscal year ended March 2026 / Amount ¥255,025 thousand, Field Implementation of a data management system using barcodes and other technologies / Timing Fiscal year ending March 2028 / Amount ¥240,000 thousand, Field Renovation of existing facilities and installation of equipment for powdered culture media by establishing a GMP-compliant production system in anticipation of entering the powdered culture media market / Timing Fiscal year ending March 2030 / Amount ¥300,000 thousand, Field Installation of emergency power supply equipment / Timing Fiscal year ending March 2028 / Amount ¥92,143 thousand
Key initiatives
01Strategy 1: Tissue Culture Business Growth Strategy (by segment)
02Product development targeting global markets
03Strategy 2: Microbiology Business Growth Strategy (by segment)
04Development of medical antigen test kits for infectious diseases
05Expansion of products under development for test kits for general consumers
06Strategy 3: Cell Processing Business Growth Strategy (by segment)
07Entry into contract manufacturing of regenerative medicine products and other products
Plan assumptionsFor customers from whom the company can receive purchasing plans, the figures are based on those plans. For other customers, the figures are calculated by multiplying the unit price, calculated from transaction results for the most recent 2 periods, by the sales volume, calculated based on expected annual demand and the market growth rate, and then aggregating the results. The market growth rate as a numerical figure is not disclosed.
Segment targetSegment Tissue Culture Business / Sales Target As stated in the table titled Business Plan, Revenue Trends and Medium-Term Plan (by segment) / Profit Target Not disclosed, Segment Microbiology Business / Sales Target As stated in the table titled Business Plan, Revenue Trends and Medium-Term Plan (by segment) / Profit Target Not disclosed, Segment Cell Processing Business / Sales Target As stated in the table titled Business Plan, Revenue Trends and Medium-Term Plan (by segment) / Profit Target Not disclosed
Size of the Target MarketMarket Culture media for cell culture in Japan (liquid media) / Scale Approximately ¥8.4 billion (estimated market size in 2025) / Share Approximately 16.7% / Source Current Status and Future Outlook of Markets Related to Regenerative Medicine and New Drug Modality Drug Discovery Support 2025 (Fuji Keizai), Market Culture media for bacterial testing in the clinical field / Scale Approximately ¥8.3 billion (estimated actual market size in 2023) / Share Approximately 5.0% / Source 2023 Markets for Genomic Analysis and IVD Genetic, Bacterial and Pathological Testing in the Spotlight (Fuji Keizai), Market Regenerative medicine and cell therapy in the self-pay medical care segment / Scale ¥28.0 billion (estimated market size in 2025) / Source Current Status and Future Outlook of Markets Related to Regenerative Medicine and New Drug Modality Drug Discovery Support 2025 (Seed Planning); Thorough Survey of the Self-Pay Market (Fuji Keizai), Market Contract Cell Processing / Scale Approximately ¥7.0 billion (2025) / Share Approximately 12.2% / Source Not disclosed, Market Global culture media for cell culture / Scale Approximately USD 5 billion–USD 6 billion / Source Not disclosed
Risks identified by the company
Competition from major foreign companies
Impact of investment trends in biopharmaceuticals
Progress in automation and rapid testing in the clinical field
Fluctuations in demand for infectious disease-related products
Demand fluctuations specific to self-pay medical care and the possibility of tighter regulation
High proportion of inbound demand and the impact of international relations
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Strategy (Medium-Term Plan) |
| Plan period | From the fiscal year ending March 2026 onward (planned figures for the fiscal years ending March 2027 to March 2029) |
| Progress against the plan | Annual update |
| Sales Target | Results for the fiscal year ended March 2026: 4,939 → Plan for the fiscal year ending March 2029: 6,088（23.3%） |
| Operating profit target | Results for the fiscal year ended March 2026: 341 → Plan for the fiscal year ending March 2029: 785（130.2%） |
| Net income target | Results for the fiscal year ended March 2026: 251 → Plan for the fiscal year ending March 2029: 479（90.8%） |
| Investment amount by sector | Field Facilities for storing products and raw materials, including break rooms and changing rooms / Timing Fiscal year ended March 2026 / Amount ¥255,025 thousand, Field Implementation of a data management system using barcodes and other technologies / Timing Fiscal year ending March 2028 / Amount ¥240,000 thousand, Field Renovation of existing facilities and installation of equipment for powdered culture media by establishing a GMP-compliant production system in anticipation of entering the powdered culture media market / Timing Fiscal year ending March 2030 / Amount ¥300,000 thousand, Field Installation of emergency power supply equipment / Timing Fiscal year ending March 2028 / Amount ¥92,143 thousand |
| Segment target | Segment Tissue Culture Business / Sales Target As stated in the table titled Business Plan, Revenue Trends and Medium-Term Plan (by segment) / Profit Target Not disclosed, Segment Microbiology Business / Sales Target As stated in the table titled Business Plan, Revenue Trends and Medium-Term Plan (by segment) / Profit Target Not disclosed, Segment Cell Processing Business / Sales Target As stated in the table titled Business Plan, Revenue Trends and Medium-Term Plan (by segment) / Profit Target Not disclosed |
| Plan assumptions | For customers from whom the company can receive purchasing plans, the figures are based on those plans. For other customers, the figures are calculated by multiplying the unit price, calculated from transaction results for the most recent 2 periods, by the sales volume, calculated based on expected annual demand and the market growth rate, and then aggregating the results. The market growth rate as a numerical figure is not disclosed. |
| Key initiatives | Strategy 1: Tissue Culture Business Growth Strategy (by segment), Product development targeting global markets, Strategy 2: Microbiology Business Growth Strategy (by segment), Development of medical antigen test kits for infectious diseases, Expansion of products under development for test kits for general consumers, Strategy 3: Cell Processing Business Growth Strategy (by segment), Entry into contract manufacturing of regenerative medicine products and other products |
| Size of the Target Market | Market Culture media for cell culture in Japan (liquid media) / Scale Approximately ¥8.4 billion (estimated market size in 2025) / Share Approximately 16.7% / Source Current Status and Future Outlook of Markets Related to Regenerative Medicine and New Drug Modality Drug Discovery Support 2025 (Fuji Keizai), Market Culture media for bacterial testing in the clinical field / Scale Approximately ¥8.3 billion (estimated actual market size in 2023) / Share Approximately 5.0% / Source 2023 Markets for Genomic Analysis and IVD Genetic, Bacterial and Pathological Testing in the Spotlight (Fuji Keizai), Market Regenerative medicine and cell therapy in the self-pay medical care segment / Scale ¥28.0 billion (estimated market size in 2025) / Source Current Status and Future Outlook of Markets Related to Regenerative Medicine and New Drug Modality Drug Discovery Support 2025 (Seed Planning); Thorough Survey of the Self-Pay Market (Fuji Keizai), Market Contract Cell Processing / Scale Approximately ¥7.0 billion (2025) / Share Approximately 12.2% / Source Not disclosed, Market Global culture media for cell culture / Scale Approximately USD 5 billion–USD 6 billion / Source Not disclosed |
| Risks identified | Competition from major foreign companies, Impact of investment trends in biopharmaceuticals, Progress in automation and rapid testing in the clinical field, Fluctuations in demand for infectious disease-related products, Demand fluctuations specific to self-pay medical care and the possibility of tighter regulation, High proportion of inbound demand and the impact of international relations |
| Publication date | May 2026 |
Items this document does not state (12)
Operating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planNon-financial targetsResults under the previous planReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited the continued maturity and contraction of the market for infectious disease-related products, the growing establishment of demand for household stockpiles among general consumers, and the increasing activity in research and development and clinical trials for regenerative medicine, gene therapy and biopharmaceuticals as the background to its business plan.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.